FRONTOTEMPORAL DEMENTIA

This study tests a single dose of PBFT02 gene therapy in 30 adults with frontotemporal dementia (FTD) caused by GRN or C9ORF72 gene mutations. The therapy delivers a working copy of the GRN gene to the brain to boost a key protein. Researchers are checking safety and whether it c…

This study tests an experimental drug called DNL593 for frontotemporal dementia, a brain disease that affects personality and language. First, healthy volunteers receive a single dose to check safety. Then, people with the disease receive multiple doses over 25 weeks to see if it…

This early-stage study tests a gene therapy (LY3884963) in 35 adults with frontotemporal dementia caused by a specific genetic mutation (GRN). The therapy aims to restore levels of a key protein (progranulin) that is low in these patients. Researchers will monitor safety, side ef…

This study tests whether metformin, a common diabetes medicine, is safe for people with a specific genetic type of ALS (C9orf72 ALS). About 41 participants will take metformin for 24 weeks. Researchers will monitor side effects and check if the drug lowers harmful proteins linked…

This study explores whether playing rhythmic music together can improve social attention and feelings of closeness in people with mild to moderate frontotemporal dementia or Alzheimer's disease, along with their caregivers. About 80 patient-caregiver pairs will take part in music…

This study tests a new way to match dementia caregivers with each other for emotional support using a computer algorithm. Researchers want to see if matching based on personal preferences leads to better satisfaction and less stress than random matching. About 355 caregivers of p…

This study looks at a protein called neurofilament light chain in the blood of people who may develop frontotemporal dementia due to family genes. Researchers want to see if levels of this protein change over time and can be measured reliably from blood samples collected at home.…

This study asks 1,000 people with neurological diseases (like Alzheimer's or Parkinson's) and their caregivers to try a head device called MemorEM and share their thoughts. The goal is to learn how to improve the device's design and make it easier to use in future studies. It is …

This study aims to learn more about ALS and similar neurodegenerative diseases by looking at how a person's genetic makeup relates to their symptoms. Researchers will also search for biomarkers—biological signs that can help track or diagnose these conditions. About 217 adults wi…

This study enrolls people with ALS and related disorders, as well as healthy volunteers, to track biological markers (biomarkers) in urine, blood, and spinal fluid. The goal is to better understand how these markers change over time, which could help design more effective future …

This study is testing whether a wearable pendant sensor can reliably track movement symptoms in 60 people with progressive supranuclear palsy (PSP) and related disorders over 12 months. Participants wear the sensor at home for 7 days each month and also have in-person checkups ev…